Jun 30, 2023

Clover Health Q2 2023 Earnings Report

Reported improved financial performance and guidance ranges.

Key Takeaways

Clover Health reported revenue of $513.6 million and a net loss of $28.8 million. Adjusted EBITDA improved to a profit of $10.0 million, and insurance revenue grew by 17% compared to Q2'22.

Insurance revenue grew 17% compared to Q2'22.

Second quarter Insurance MCR improved to 77.2%, bringing first half MCR to 81.9%.

Company reports Q2 Net Loss of $28.8 million.

Adjusted EBITDA profit of $10.0 million.

Total Revenue
$514M
Previous year: $847M
-39.3%
EPS
-$0.06
Previous year: -$0.22
-72.7%
Gross Profit
$76.7M
Previous year: -$12.1M
-734.4%
Cash and Equivalents
$690M
Previous year: $324M
+112.6%
Free Cash Flow
$52.8M
Previous year: -$39.3M
-234.2%
Total Assets
$1.26B
Previous year: $2.06B
-39.0%

Clover Health

Clover Health

Forward Guidance

Clover Health is providing its guidance for full-year 2023.

Positive Outlook

  • Insurance revenue is expected to be in the range of $1.20 billion to $1.23 billion in 2023, a growth rate of 11% - 13% as compared to full year 2022 Insurance revenue.
  • Insurance MCR is expected to be in the range of 83% - 85% in 2023.
  • Non-Insurance revenue is expected to be in the range of $0.75 billion to $0.80 billion in 2023.
  • Non-Insurance MCR is expected to be in the range of 98% - 100% in 2023.
  • Adjusted SG&A (non-GAAP) is expected to be between $315 million and $325 million.

Challenges Ahead

  • Adjusted EBITDA (non-GAAP) is expected to be between ($70 million) and ($120 million).